SUMMARY, EXPLANATION AND LIMITATIONS:
The determination of steroid hormone receptors is of great importance for therapy of patients with hormone receptor expressing tumours. Expression of progesterone receptors in tumour cells of human breast carcinoma points to an intact estrogen receptor and to sensitivity of this tumour to endocrine therapy. The progesterone receptor content is therefore a marker for response to hormone therapy.
The method mainly used for determination of hormone receptors is immunohistochemistry. Progesterone and estrogen receptor positive breast carcinoma patients have demonstrated a better response to endocrine therapy than receptor negative patients. Therefore, steroid hormone receptors are positive prognostic factors. Use of monoclonal antibodies for determination of receptor status increases the predictive value concerning response to the therapy.
Immunogen: Recombinant progesterone receptor protein.
Staining pattern: Nuclear.
Positive control: Tissue sample from breast carcinoma.
This antibody is designed for the specific localization of human progesterone receptor using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.